Women's Health

The Pharmacy Times® Women’s Health resource center provides clinical news and articles, pertaining to women’s wellness, nutrition, fitness, weight loss, and answers to other potentially more intimate questions.

What can we help you find?
[[thumbnail_alt_text]]
Attendees at the McKesson ideaShare had the chance to hear about women pharmacists and the challenges, successes, and opportunities they have in a session presented by Suzanne Soliman, PharmD.
[[thumbnail_alt_text]]
The effectiveness and safety of bremelanotide were studied in a pair of 24-week, randomized, double-blind, placebo-controlled trials in 1247 premenopausal women with acquired, generalized HSDD.
[[thumbnail_alt_text]]
A progestin-only pill, this estrogen-free oral contraceptive is intended as a 24 active and 4 inactive tablet dosing regimen.
[[thumbnail_alt_text]]
Contraceptives are both a popular and effective birth control method, and Medicaid fully covers them for its beneficiaries.
[[thumbnail_alt_text]]
Uncontrolled diabetes in pregnancy can lead to preeclampsia, cesarean delivery, preterm delivery, significant overgrowth in the child, and congenital defects.
[[thumbnail_alt_text]]
This report revealed that in 2016, an estimated 3900 of 4200 or 93% incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women.
[[thumbnail_alt_text]]
The commercial availability of Bijuva offers an FDA approved alternative to marketed synthetic hormones or individual estrogen and progesterone products that have not been FDA-approved for combination use. 
[[thumbnail_alt_text]]
Approved by the FDA on April 9, 2019, Amgen’s romosozumab-aqqg therapy (Evenity) is indicated for osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
[[thumbnail_alt_text]]
The action requires the company to revise safety information that women and their health care professionals need when considering use of the drug.
[[thumbnail_alt_text]]
Romosozumab-aqqg (Evenity, Amgen) works to decrease the risk of fracture by increasing new bone formation in women with postmenopausal osteoporosis.
[[thumbnail_alt_text]]
This therapy is expected to become available in late June.
[[thumbnail_alt_text]]
Indicating for preventing pregnancy, a statement from the FDA said that loss of efficacy is possible if the user misses tablets.